Boothbay Fund Management LLC Has $16.96 Million Holdings in Maze Therapeutics, Inc. $MAZE

Boothbay Fund Management LLC lifted its holdings in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 16.3% in the 4th quarter, Holdings Channel reports. The firm owned 409,372 shares of the company’s stock after buying an additional 57,497 shares during the quarter. Boothbay Fund Management LLC’s holdings in Maze Therapeutics were worth $16,960,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Freestone Grove Partners LP acquired a new position in shares of Maze Therapeutics during the fourth quarter valued at about $4,925,000. Caligan Partners LP bought a new stake in Maze Therapeutics in the fourth quarter valued at about $22,794,000. ADAR1 Capital Management LLC increased its stake in Maze Therapeutics by 589.3% in the fourth quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after acquiring an additional 153,487 shares during the period. MPM Bioimpact LLC bought a new stake in Maze Therapeutics in the fourth quarter valued at about $3,362,000. Finally, ArrowMark Colorado Holdings LLC increased its stake in Maze Therapeutics by 40.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company’s stock valued at $31,793,000 after acquiring an additional 222,251 shares during the period.

Maze Therapeutics Stock Up 4.1%

Shares of MAZE stock opened at $24.84 on Thursday. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 1 year low of $9.83 and a 1 year high of $53.65. The firm’s fifty day moving average price is $25.83 and its two-hundred day moving average price is $36.61. The firm has a market capitalization of $1.37 billion, a P/E ratio of -9.82 and a beta of 2.26.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. On average, equities analysts predict that Maze Therapeutics, Inc. will post -2.76 EPS for the current fiscal year.

Analyst Ratings Changes

MAZE has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. HC Wainwright increased their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Truist Financial lowered their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Guggenheim lifted their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and an average target price of $66.00.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 15,000 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $26.22, for a total value of $393,300.00. Following the transaction, the chief marketing officer directly owned 15,000 shares of the company’s stock, valued at $393,300. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total transaction of $73,600.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $381,689.60. The trade was a 16.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 89,502 shares of company stock valued at $2,733,139 in the last 90 days. Insiders own 5.30% of the company’s stock.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.